The present invention is directed to methods and formulations for treating, modifying, and/or managing gastrointestinal secretion, and intestinal conditions that cause the same. Methods of using at least one .alpha.3 .beta.4 nAChR antagonist and formulations comprising at least one .alpha.3 .beta.4 nAChR antagonist, or pharmaceutically acceptable salt thereof, are included.